How has Denali Therapeutics Inc.'s other commercial liabilities changed year-over-year?

Denali Therapeutics Inc.'s other commercial liabilities increased by 848.8% year-over-year, from $7.35M to $69.78M.

What is the long-term trend for Denali Therapeutics Inc.'s other commercial liabilities?

Over 4 years (2020 to 2025), Denali Therapeutics Inc.'s other commercial liabilities has grown at a 85.2% compound annual growth rate (CAGR), from $8.32M to $97.85M.

Denali Therapeutics Inc. DNLI Other Commercial Liabilities

Other Commercial Liabilities at other companies

Ultragenyx PharmaceuticalRARE

——

uniQureQURE

——

Acadia PharmaceuticalsACAD

——

ALN

Alnylam PharmaceuticalsALNY

——

Praxis Precision Medicines, Inc.PRAX

——

Relay Therapeutics, Inc.RLAY

——

Other financials

Income statement

See full

Revenue-—

Operating income-$137.4M+5.6%

Net income-$128.4M+3.4%

EPS (diluted)-$0.69+11.5%

Balance sheet

See full

Cash & equivalents$390.7M+551%

Total debt$40.0M-22.3%

Total equity$926.1M-17.5%

Total assets$1.3B-0.4%

Cash flow

See full

Operating cash flow-$131.2M+0.2%

CapEx$2.5M-51.4%

Free cash flow-$133.7M+2.1%

Valuation

See full

Market cap$3.93B+54.2%

Profitability

See full

Operating margin-37,938%-37,986pp

Net margin-33,121.9%-33,159pp

FCF margin-31,736.3%-31,830pp

Returns & leverage

See full

Return on equity-49.6%+34.2pp

Debt / equity0×0.0×

Current ratio9.3×-0.3×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Denali Therapeutics Inc.'s other commercial liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Denali Therapeutics Inc.'s other commercial liabilities?: Denali Therapeutics Inc. (DNLI) reported other commercial liabilities of $69.78M in Q1 2026.
How has Denali Therapeutics Inc.'s other commercial liabilities changed year-over-year?: Denali Therapeutics Inc.'s other commercial liabilities increased by 848.8% year-over-year, from $7.35M to $69.78M.
What is the long-term trend for Denali Therapeutics Inc.'s other commercial liabilities?: Over 4 years (2020 to 2025), Denali Therapeutics Inc.'s other commercial liabilities has grown at a 85.2% compound annual growth rate (CAGR), from $8.32M to $97.85M.